| 2025-12-15 |
详情>>
内部人交易：
ORDAN MARK S股份减少23000.00股
|
| 2025-11-03 |
详情>>
股本变动：
变动后总股本8587.74万股
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.56美元,归母净利润1.32亿美元,同比去年增长201.66%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘前发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益0.71美元,归母净利润5999.70万美元,同比去年增长140.27%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益0.25美元,归母净利润2073.70万美元,同比去年增长413.93%
|
| 2025-03-28 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.To elect, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified, the following individuals to Pediatrix’s Board of Directors: Laura A. Linynsky, Thomas A. McEachin, Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr., Shirley A. Weis and Sylvia J. Young;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2025 fiscal year;
3.To conduct an advisory vote regarding the compensation of our named executive officers for the 2024 fiscal year;
4.To consider and act upon such other business as may properly come before the annual meeting.
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益-1.19美元,归母净利润-9906.9万美元,同比去年增长-64%
|
| 2025-02-20 |
详情>>
业绩披露：
2022年年报每股收益0.79美元,归母净利润6633.50万美元,同比去年增长-49.35%
|
| 2024-11-01 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.56美元,归母净利润-1.3亿美元,同比去年增长-302.8%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-1.79美元,归母净利润-1.49亿美元,同比去年增长-450.66%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益0.52美元,归母净利润4248.80万美元,同比去年增长614.32%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益0.05美元,归母净利润403.50万美元,同比去年增长-71.6%
|
| 2024-03-28 |
股东大会：
将于2024-05-09召开股东大会
会议内容 ▼▲
- 1.To elect, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified, the following individuals to Pediatrix’s Board of Directors: Laura A. Linynsky, Thomas A. McEachin, Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr., James D. Swift, M.D., Shirley A. Weis and Sylvia J. Young;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2024 fiscal year;
3.To conduct an advisory vote regarding the compensation of our named executive officers for the 2023 fiscal year;
4.To consider and act upon such other business as may properly come before the annual meeting.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益-0.73美元,归母净利润-6040.8万美元,同比去年增长-191.07%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.78美元,归母净利润6387.90万美元,同比去年增长74.17%
|
| 2023-03-31 |
股东大会：
将于2023-05-11召开股东大会
会议内容 ▼▲
- 1.To elect, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified, the following individuals to Pediatrix’s Board of Directors: Laura A. Linynsky, Thomas A. McEachin, Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr., James D. Swift, M.D. and Shirley A. Weis;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2023 fiscal year;
3.To conduct an advisory vote regarding the compensation of our named executive officers for the 2022 fiscal year;
4.To cast an advisory vote on the frequency of holding future advisory votes on executive compensation;
5.To consider and act upon such other business as may properly come before the annual meeting.
|
| 2022-04-01 |
股东大会：
将于2022-05-12召开股东大会
会议内容 ▼▲
- 1.to elect, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified, the following individuals to Mednax’s Board of Directors: Laura A. Linynsky, Thomas A. McEachin, Roger J. Medel, M.D., Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr. and Shirley A. Weis;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2022 fiscal year;
3.to conduct an advisory vote regarding the compensation of our named executive officers for the 2021 fiscal year;
4.to approve our Second Amended and Restated Articles of Incorporation;
5.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-23 |
股东大会：
将于2021-05-12召开股东大会
会议内容 ▼▲
- 1.to elect, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified, the following individuals to Mednax’s Board of Directors: Karey D. Barker, Waldemar A. Carlo, M.D., Paul G. Gabos, Manuel Kadre, Thomas A. McEachin, Roger J. Medel, M.D., Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr. and Shirley A. Weis;
2.to approve the amendment and restatement of the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan;
3.to approve the amendment and restatement of the Mednax, Inc. 1996 Non-Qualified Employee Stock Purchase Plan, as amended;
4.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2021 fiscal year;
5.to conduct an advisory vote regarding the compensation of our named executive officers for the 2020 fiscal year;
6.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2020-07-28 |
股东大会：
将于2020-09-09召开股东大会
会议内容 ▼▲
- 1.to elect, each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified, the following individuals to MEDNAX’s Board of Directors: Karey D. Barker, Waldemar A. Carlo, M.D., Paul G. Gabos, Manuel Kadre, Thomas A. McEachin, Roger J. Medel, M.D., Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr. and Shirley A. Weis;
2.to approve the Articles of Amendment to our Amended and Restated Articles of Incorporation, as amended, to change the Company’s name to “Pediatrix Medical Group, Inc.”;
3.to approve the Articles of Amendment to the Amended and Restated Articles of Incorporation, as amended, of MEDNAX Services, Inc., a subsidiary of the Company, to change its name to “PMG Services, Inc.”
4.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2020 fiscal year;
5.to conduct an advisory vote regarding the compensation of our named executive officers for the 2019 fiscal year;
6.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2019-03-29 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.to elect Roger J. Medel, M.D., Cesar L. Alvarez, Karey D. Barker, Waldemar A. Carlo, M.D., Michael B. Fernandez, Paul G. Gabos, Pascal J. Goldschmidt, M.D., Manuel Kadre, Carlos A. Migoya, Michael A. Rucker and Enrique J. Sosa, Ph.D. as Directors, each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2019 fiscal year;
3.to conduct an advisory vote approving MEDNAX’s executive compensation;
4.to approve the amendment and restatement of the MEDNAX, Inc. Amended and Restated 2008 Incentive Compensation Plan, as amended;
5.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2018-03-23 |
股东大会：
将于2018-05-16召开股东大会
会议内容 ▼▲
- 1.to elect Roger J. Medel, M.D., Cesar L. Alvarez, Karey D. Barker, Waldemar A. Carlo, M.D., Michael B. Fernandez, Paul G. Gabos, Pascal J. Goldschmidt, M.D., Manuel Kadre and Enrique J. Sosa, Ph.D. as Directors, each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2018 fiscal year;
3.to cast an advisory vote approving MEDNAX’s executive compensation;
4.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2017-12-02 |
复牌提示：
2017-12-01 11:48:27 停牌，复牌日期 2017-12-01 11:53:47
|
| 2017-03-17 |
股东大会：
将于2017-05-11召开股东大会
会议内容 ▼▲
- 1.to elect Roger J. Medel, M.D., Cesar L. Alvarez, Karey D. Barker, Waldemar A. Carlo, M.D., Michael B. Fernandez, Paul G. Gabos, Pascal J. Goldschmidt, M.D., Manuel Kadre, Donna E. Shalala, Ph.D. and Enrique J. Sosa, Ph.D. as Directors, each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified;
2.to re-approve the material terms of the performance goals under the MEDNAX, Inc. Amended and Restated 2008 Incentive Compensation Plan, as amended, for purposes of Section 162(m) of the Internal Revenue Code;
3.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered certified public accounting firm for the 2017 fiscal year;
4.to cast an advisory vote approving MEDNAX’s executive compensation;
5.to cast an advisory vote on the frequency of holding future advisory votes on executive compensation;
6.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2016-03-18 |
股东大会：
将于2016-05-12召开股东大会
会议内容 ▼▲
- 1.to elect Roger J. Medel, M.D., Cesar L. Alvarez, Karey D. Barker, Waldemar A. Carlo, M.D., Michael B. Fernandez, Paul G. Gabos, Pascal J. Goldschmidt, M.D., Manuel Kadre, Donna E. Shalala, Ph.D. and Enrique J. Sosa, Ph.D. as Directors, each for a term expiring at the next annual meeting or until his or her successor has been duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered certified public accounting firm for the 2016 fiscal year;
3.to cast an advisory vote approving MEDNAX’s executive compensation;
4.to consider and act upon such other business as may properly come before the annual meeting.
|
| 2015-09-18 |
股东大会：
将于2015-11-03召开股东大会
会议内容 ▼▲
- 1.to approve the proposed Amended and Restated MEDNAX, Inc. 1996 Non-Qualified Employee Stock Purchase Plan, which is being amended and restated to increase the number of shares of our common stock reserved for issuance thereunder;
2.to approve the creation of the MEDNAX, Inc. 2015 Non-Qualified Stock Purchase Plan, which is being proposed to enable MEDNAX’s eligible independent contractors to invest in MEDNAX through purchases of MEDNAX common stock at a favorable price through deductions from payments made for independent contractor services;
3.to consider and act upon such other business as may properly come before the special meeting.
|